News about our AI-native drug discovery
News
ValidaTe just gave the answer to one of the hardest problems in TCRm-based immunotherapy: how to systematically predict and eliminate off-target toxicity before it kills the program in the clinic.
As part of a Series A financing round scheduled to close on March 31, 2026, Haute Capital Partners has made a strategic investment in BioCopy
With the publication of EpiTox, all three components of our ValidaTe platform are now publicly validated and available.
EpiPredict delivers a new level of confidence for safety assessment in TCR like drug modalities and provides a powerful solution for developers of T cell receptor mimic (TCRm) antibodies.
“Revolutionizing Cancer Drug Development with AI: How BioCopy is Using Physics to Rewrite the Rules of Biotech”
WirtschaftsWoche has selected Matthias Wiedenfels as a winner of “Germany's 30 by 2030”
Next step towards BioCopys AI-powered high-quality engineering of next-generation cancer therapeutics
Recent company developments across operations, financing, and organizational build out.
“Revolutionizing Cancer Drug Development with AI: How BioCopy is Using Physics to Rewrite the Rules of Biotech”